Steroid receptors in breast cancer

K. Cowan, Marc E Lippman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.

Original languageEnglish
Pages (from-to)363-366
Number of pages4
JournalArchives of Internal Medicine
Volume142
Issue number2
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Steroid Receptors
Breast Neoplasms
Progesterone Receptors
Estrogen Receptors
Therapeutics
Neoplasms
Estrogens
Physicians
Drug Therapy

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Steroid receptors in breast cancer. / Cowan, K.; Lippman, Marc E.

In: Archives of Internal Medicine, Vol. 142, No. 2, 01.01.1982, p. 363-366.

Research output: Contribution to journalArticle

Cowan, K. ; Lippman, Marc E. / Steroid receptors in breast cancer. In: Archives of Internal Medicine. 1982 ; Vol. 142, No. 2. pp. 363-366.
@article{d7f6fd939ac54d189dd5d38a4da76f99,
title = "Steroid receptors in breast cancer",
abstract = "The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.",
author = "K. Cowan and Lippman, {Marc E}",
year = "1982",
month = "1",
day = "1",
doi = "10.1001/archinte.142.2.363",
language = "English",
volume = "142",
pages = "363--366",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Steroid receptors in breast cancer

AU - Cowan, K.

AU - Lippman, Marc E

PY - 1982/1/1

Y1 - 1982/1/1

N2 - The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.

AB - The authors have reviewed some of the possible reasons for the lack of complete correlation between tumor estrogen-receptor analysis and response to endocrine therapy in the present article. While the analysis of progesterone receptors in breast cancer seems to have improved the ability to select patients for endocrine therapy, it is still not completely predictive. Other measures of estrogen responsiveness are currently under investigation. A wide variety of ablative and additive endocrine therapies have been used successfully in patients with breast cancer. In addition, numerous cytotoxic chemotherapy regimens have proved effective in the treatment of this disease. Whenever possible, tumor samples should be obtained for both estrogen- and progesterone-receptor analysis before any therapy is started. Once this information is obtained, the physician can then make a decision regarding therapy, which would have a high probability of success while minimizing the risk to the patient.

UR - http://www.scopus.com/inward/record.url?scp=0020062047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020062047&partnerID=8YFLogxK

U2 - 10.1001/archinte.142.2.363

DO - 10.1001/archinte.142.2.363

M3 - Article

C2 - 7036926

AN - SCOPUS:0020062047

VL - 142

SP - 363

EP - 366

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 2

ER -